{
  "ticker": "UNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973194",
  "id": "02973194",
  "pages": 15,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0934",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6cvrf5f36bp.pdf",
  "summary": "### **UNITH Ltd \u2013 Quarterly Activities Report (June 2025) \u2013 Material Summary**  \n\n#### **Financial Highlights (Appendix 4C)**  \n- **Cash receipts (Q4 FY25):** $1.60M (+19% QoQ).  \n- **FY25 unaudited cash receipts:** $5.35M (+7.6% YoY).  \n- **Cash balance (30 June 2025):** $0.45M.  \n- **Post-quarter capital raise:** $1.85M (binding commitments).  \n- **Net operating cash outflow (Q4):** -$0.14M (improving trend).  \n\n#### **Operational Highlights (Material Impact)**  \n- **New clients:** 240 organizations onboarded.  \n- **Platform traction:** 2,100+ Digital Humans created; 81% actively engaged.  \n- **Strategic partnership:** Collaboration with Spectar Group/Specia.AI (IPA/AI solutions).  \n- **Pharma MVP delivered:** Pilot with global pharma client (regulatory use case).  \n- **B2C division:**  \n  - Revenue: $1.20M (-5% YoY), but margins improved 20%.  \n  - European expansion: Telco partnerships (MEO Portugal, KPN Netherlands).  \n\n#### **Capital Markets Implications**  \n- **Liquidity post-raise:** Pro forma cash ~$2.19M.  \n- **Funding runway:** ~3.3 quarters (per Appendix 4C).  \n\n**Summary:** Strong revenue growth and partnerships offset by tight liquidity; capital raise extends runway. Focus on pharma/enterprise adoption and margin improvements.  \n\n*Omitted: Website updates, hiring, non-material partnerships.*",
  "usage": {
    "prompt_tokens": 8232,
    "completion_tokens": 361,
    "total_tokens": 8593,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:47:17.543443"
}